232 reports of this reaction
1.5% of all MICAFUNGIN SODIUM reports
#14 most reported adverse reaction
SEPTIC SHOCK is the #14 most commonly reported adverse reaction for MICAFUNGIN SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 232 FDA adverse event reports linking MICAFUNGIN SODIUM to SEPTIC SHOCK. This represents approximately 1.5% of all 15,554 adverse event reports for this drug.
Patients taking MICAFUNGIN SODIUM who experience septic shock should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEPTIC SHOCK is a less commonly reported adverse event for MICAFUNGIN SODIUM, but still significant enough to appear in the safety profile.
In addition to septic shock, the following adverse reactions have been reported for MICAFUNGIN SODIUM:
The following drugs have also been linked to septic shock in FDA adverse event reports:
SEPTIC SHOCK has been reported as an adverse event in 232 FDA reports for MICAFUNGIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEPTIC SHOCK accounts for approximately 1.5% of all adverse event reports for MICAFUNGIN SODIUM, making it a notable side effect.
If you experience septic shock while taking MICAFUNGIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.